This result was consistent with the results performed in the CH12F3 B-cell lymphoma cell line based CSR assay showing that PAXX was dispensable for CSR cNHEJ in the presence or absence of XLF (53). Here, PAXX is linked to B-cell non-Hodgkin lymphoma.